SEC Form 4 · accession 0001104659-18-011695
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy B Lowinger
Officer — Chief Scientific Officer
Period of report
Feb 21, 2018
Accepted (ET)
Feb 23, 2018 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2018 | M | 5,911 | $6.98 | A | 5,911 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $6.98 | Feb 21, 2018 | M | 5,911 | D | — | Mar 3, 2018 | Common Stock | 5,911 | 0 | D |
Explanation of responses
- F1The option vested 25% on February 11, 2009 and in equal quarterly installments thereafter.